Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for Kenneth Allen Myszkowski. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at Kenneth Allen Myszkowski har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:ARWR / Arrowhead Pharmaceuticals, Inc. | Chief Financial Officer | 455 433 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av Kenneth Allen Myszkowski. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av Kenneth Allen Myszkowski som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-01-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −10 000 | 455 433 | −2,15 | 19,69 | −196 900 | 8 967 476 | |
2025-01-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −8 000 | 465 433 | −1,69 | 19,70 | −157 600 | 9 169 030 |
2025-01-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −9 402 | 473 433 | −1,95 | 20,10 | −188 980 | 9 516 003 |
2025-01-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −17 765 | 482 835 | −3,55 | 19,68 | −349 615 | 9 502 193 |
2025-01-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 100 000 | 500 600 | 24,96 | ||||
2024-03-08 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −40 000 | 400 600 | −9,08 | 35,19 | −1 407 600 | 14 097 114 | |
2024-01-08 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −8 904 | 440 600 | −1,98 | 35,65 | −317 428 | 15 707 390 |
2024-01-08 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −5 800 | 449 504 | −1,27 | 34,97 | −202 826 | 15 719 155 |
2024-01-08 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 400 | 455 304 | −0,31 | 34,04 | −47 656 | 15 498 548 |
2024-01-08 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 75 000 | 456 704 | 19,65 | ||||
2023-06-29 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −15 000 | 381 704 | −3,78 | 36,20 | −543 000 | 13 817 685 | |
2023-01-05 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 60 000 | 396 704 | 17,82 | ||||
2022-12-30 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −30 625 | 336 704 | −8,34 | 40,00 | −1 225 000 | 13 468 160 |
2022-09-30 |
|
5 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
G - Gift | −96 676 | 367 329 | −20,84 | ||||
2022-01-06 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 786 | 464 005 | −0,81 | 63,95 | −242 115 | 29 673 120 |
2022-01-06 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 778 | 467 791 | −0,80 | 63,17 | −238 656 | 29 550 357 |
2022-01-06 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −16 528 | 471 569 | −3,39 | 62,00 | −1 024 736 | 29 237 278 |
2022-01-06 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −15 908 | 488 097 | −3,16 | 60,50 | −962 434 | 29 529 868 |
2022-01-04 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 60 000 | 504 005 | 13,51 | ||||
2021-01-12 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 441 | 444 005 | −0,32 | 81,00 | −116 721 | 35 964 405 | |
2021-01-12 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −11 597 | 445 446 | −2,54 | 81,02 | −939 589 | 36 090 035 | |
2021-01-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −25 166 | 457 043 | −5,22 | 72,63 | −1 827 807 | 33 195 033 |
2021-01-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −4 359 | 482 209 | −0,90 | 71,77 | −312 845 | 34 608 140 |
2021-01-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 100 | 486 568 | −0,23 | 70,75 | −77 825 | 34 424 686 |
2021-01-05 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 60 000 | 487 668 | 14,03 | ||||
2020-11-12 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −43 505 | 0 | −100,00 | ||||
2020-11-12 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −17 665 | 427 668 | −3,97 | 69,86 | −1 234 077 | 29 876 886 | |
2020-11-12 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −25 840 | 445 333 | −5,48 | 69,04 | −1 783 994 | 30 745 790 | |
2020-11-12 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 43 505 | 471 173 | 10,17 | 14,54 | 632 563 | 6 850 855 | |
2020-10-22 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −29 166 | 43 505 | −40,13 | ||||
2020-10-22 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −29 166 | 427 668 | −6,38 | 54,04 | −1 576 131 | 23 111 179 | |
2020-10-22 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 29 166 | 456 834 | 6,82 | 6,15 | 179 371 | 2 809 529 | |
2020-02-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −10 834 | 72 671 | −12,97 | ||||
2020-02-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −12 116 | 83 505 | −12,67 | ||||
2020-02-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −6 495 | 95 621 | −6,36 | ||||
2020-02-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −2 000 | 102 116 | −1,92 | ||||
2020-02-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −12 000 | 104 116 | −10,33 | ||||
2020-02-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 10 834 | 427 668 | 2,60 | 6,15 | 66 629 | 2 630 158 | |
2020-02-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 12 116 | 416 834 | 2,99 | 7,75 | 93 899 | 3 230 464 | |
2020-02-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 6 495 | 404 718 | 1,63 | 14,54 | 94 437 | 5 884 600 | |
2020-02-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 2 000 | 398 223 | 0,50 | 5,19 | 10 380 | 2 066 777 | |
2020-02-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 12 000 | 396 223 | 3,12 | 9,90 | 118 800 | 3 922 608 | |
2020-01-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −33 351 | 116 116 | −22,31 | ||||
2020-01-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 450 | 384 223 | −0,89 | 52,13 | −179 848 | 20 029 545 |
2020-01-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −10 680 | 387 673 | −2,68 | 51,11 | −545 855 | 19 813 967 |
2020-01-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 800 | 398 353 | −0,70 | 49,98 | −139 944 | 19 909 683 |
2020-01-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −10 554 | 401 153 | −2,56 | 49,07 | −517 885 | 19 684 578 |
2020-01-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −6 432 | 411 707 | −1,54 | 47,93 | −308 286 | 19 733 117 |
2020-01-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −6 397 | 418 139 | −1,51 | 47,07 | −301 107 | 19 681 803 |
2020-01-23 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 33 351 | 424 536 | 8,53 | 5,19 | 173 092 | 2 203 342 | |
2020-01-08 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −500 | 391 185 | −0,13 | 60,95 | −30 475 | 23 842 726 |
2020-01-08 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −11 907 | 391 685 | −2,95 | 60,40 | −719 183 | 23 657 774 |
2020-01-08 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −7 593 | 403 592 | −1,85 | 59,60 | −452 543 | 24 054 083 |
2020-01-03 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 85 000 | 411 185 | 26,06 | ||||
2019-11-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −12 649 | 149 467 | −7,80 | ||||
2019-11-07 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 12 649 | 326 185 | 4,03 | 5,19 | 65 648 | 1 692 900 | |
2019-11-01 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −37 884 | 162 116 | −18,94 | ||||
2019-11-01 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −16 620 | 313 536 | −5,03 | 41,21 | −684 910 | 12 920 819 |
2019-11-01 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −21 264 | 330 156 | −6,05 | 40,56 | −862 468 | 13 391 127 |
2019-11-01 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 37 884 | 351 420 | 12,08 | 7,75 | 293 601 | 2 723 505 | |
2019-06-03 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −20 000 | 200 000 | −9,09 | ||||
2019-06-03 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −15 000 | 220 000 | −6,38 | ||||
2019-06-03 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 20 000 | 313 536 | 6,81 | 5,19 | 103 800 | 1 627 252 | |
2019-06-03 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 15 000 | 293 536 | 5,39 | 4,60 | 69 000 | 1 350 266 | |
2019-05-22 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −27 071 | 278 536 | −8,86 | 22,00 | −595 562 | 6 127 792 |
2019-02-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −8 000 | 235 000 | −3,29 | ||||
2019-02-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −8 000 | 305 607 | −2,55 | 18,00 | −144 000 | 5 500 926 |
2019-02-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 8 000 | 313 607 | 2,62 | 5,20 | 41 600 | 1 630 756 | |
2019-01-18 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −81 875 | 305 607 | −21,13 | 14,55 | −1 191 281 | 4 446 582 |
2019-01-03 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −8 333 | 387 482 | −2,11 | 11,98 | −99 829 | 4 642 034 | |
2019-01-03 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 85 000 | 395 815 | 27,35 | ||||
2018-09-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −20 000 | 243 000 | −7,60 | ||||
2018-09-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −25 000 | 263 000 | −8,68 | ||||
2018-09-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −20 000 | 310 815 | −6,05 | 21,01 | −420 200 | 6 530 223 |
2018-09-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −25 000 | 330 815 | −7,03 | 18,00 | −450 000 | 5 954 670 |
2018-09-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 20 000 | 355 815 | 5,96 | 4,75 | 95 000 | 1 690 121 | |
2018-09-10 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 25 000 | 335 815 | 8,04 | 2,62 | 65 500 | 879 835 | |
2018-06-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −20 000 | 288 000 | −6,49 | ||||
2018-06-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −20 000 | 310 815 | −6,05 | 14,01 | −280 200 | 4 354 518 |
2018-06-20 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 20 000 | 330 815 | 6,43 | 2,01 | 40 200 | 664 938 | |
2018-06-01 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −12 600 | 308 000 | −3,93 | ||||
2018-06-01 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −12 600 | 310 815 | −3,90 | 11,00 | −138 600 | 3 418 965 |
2018-06-01 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 12 600 | 323 415 | 4,05 | 2,01 | 25 326 | 650 064 | |
2018-06-01 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −1 400 | 320 600 | −0,43 | ||||
2018-06-01 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 400 | 310 815 | −0,45 | 11,00 | −15 400 | 3 418 965 |
2018-06-01 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 1 400 | 312 215 | 0,45 | 2,01 | 2 814 | 627 552 | |
2018-03-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −20 000 | 322 000 | −5,85 | ||||
2018-03-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −20 000 | 310 815 | −6,05 | 8,00 | −160 000 | 2 486 520 |
2018-03-27 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 20 000 | 330 815 | 6,43 | 2,01 | 40 200 | 664 938 | |
2018-03-05 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −8 208 | 310 815 | −2,57 | 6,66 | −54 665 | 2 070 028 | |
2018-01-03 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 75 000 | 319 023 | 30,73 | ||||
2017-10-06 |
|
5 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
G - Gift | −16 666 | 244 023 | −6,39 | ||||
2017-01-04 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
A - Award | 145 000 | 260 689 | 125,34 | ||||
2016-08-26 |
|
4/A | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −6 900 | 342 000 | −1,98 | ||||
2016-08-26 |
|
4/A | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −6 900 | 115 689 | −5,63 | 8,00 | −55 200 | 925 512 |
2016-08-26 |
|
4/A | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 6 900 | 122 589 | 5,96 | 2,01 | 13 869 | 246 404 | |
2016-08-26 |
|
4/A | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −13 100 | 348 900 | −3,62 | ||||
2016-08-26 |
|
4/A | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −13 100 | 115 689 | −10,17 | 8,00 | −104 800 | 925 512 |
2016-08-26 |
|
4/A | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 13 100 | 128 789 | 11,32 | 2,01 | 26 331 | 258 866 | |
2016-08-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −6 900 | 342 000 | −1,98 | ||||
2016-08-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −6 900 | 115 689 | −5,63 | 8,00 | −55 200 | 925 512 | |
2016-08-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 6 900 | 122 589 | 5,96 | 2,01 | 13 869 | 246 404 | |
2016-08-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −13 100 | 348 900 | −3,62 | ||||
2016-08-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −13 100 | 115 689 | −10,17 | 8,00 | −104 800 | 925 512 | |
2016-08-24 |
|
4 | ARWR |
ARROWHEAD PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 13 100 | 128 789 | 11,32 | 2,01 | 26 331 | 258 866 | |
2016-03-08 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
F - Taxes | −6 263 | 115 689 | −5,14 | 4,33 | −27 119 | 500 933 | |
2016-02-09 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
F - Taxes | −13 048 | 121 952 | −9,67 | 3,46 | −45 146 | 421 954 | |
2016-01-04 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option |
A - Award | 40 000 | 362 000 | 12,42 | ||||
2016-01-04 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
A - Award | 50 000 | 135 000 | 58,82 | ||||
2016-01-04 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
S - Sale | −23 347 | 85 000 | −21,55 | 6,13 | −143 117 | 521 050 | |
2016-01-04 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
F - Taxes | −13 153 | 108 347 | −10,83 | 6,13 | −80 628 | 664 167 | |
2015-03-06 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option |
A - Award | 50 000 | 322 000 | 18,38 | ||||
2015-03-06 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
A - Award | 50 000 | 121 500 | 69,93 | ||||
2014-08-19 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option (right to buy) |
M - Exercise | −25 000 | 272 000 | −8,42 | ||||
2014-08-19 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option (right to buy) |
M - Exercise | −15 000 | 297 000 | −4,81 | ||||
2014-08-19 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
S - Sale | −40 000 | 71 500 | −35,87 | 14,02 | −560 860 | 1 002 537 | |
2014-08-19 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
M - Exercise | 25 000 | 111 500 | 28,90 | 7,00 | 175 000 | 780 500 | |
2014-08-19 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
M - Exercise | 15 000 | 86 500 | 20,98 | 5,19 | 77 850 | 448 935 | |
2014-02-12 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option |
M - Exercise | −16 000 | 312 000 | −4,88 | ||||
2014-02-12 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
S - Sale | −16 000 | 71 500 | −18,29 | 18,77 | −300 290 | 1 341 919 | |
2014-02-12 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
M - Exercise | 16 000 | 87 500 | 22,38 | 2,01 | 32 160 | 175 875 | |
2014-02-10 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Options |
A - Award | 50 000 | 328 000 | 17,99 | ||||
2014-02-10 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Common Stock |
A - Award | 70 000 | 71 500 | 4 666,67 | ||||
2013-09-24 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option |
A - Award | 20 000 | 278 000 | 7,75 | ||||
2013-05-08 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option |
A - Award | 90 000 | 258 000 | 53,57 | ||||
2012-10-02 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option |
A - Award | 25 000 | 168 000 | 17,48 | ||||
2012-02-21 |
|
4 | ARWR |
ARROWHEAD RESEARCH CORP
Stock Option |
A - Award | 83 000 | 143 000 | 138,33 |